http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020525401-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-80 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C219-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-42 |
| filingDate | 2018-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020525401-A |
| titleOfInvention | Crystalline and amorphous forms of the dezocine analog hydrochloride. |
| abstract | The present invention relates to crystalline forms and amorphous forms of dezocine analog hydrochlorides, and in particular to crystalline forms of compounds of formula (I) and amorphous forms of compounds of formula (II), The X-ray powder diffraction spectrum of the crystalline form contains characteristic peaks with 2θ values of 13.07°±0.2°, 16.84°±0.2° and 18.51°±0.2°, The amorphous X-ray powder diffraction spectrum is shown as in FIG. |
| priorityDate | 2017-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.